BioSpace News Archive

Connect Biopharma Holdings Limited today announced that two abstracts from its CBP-201 clinical development program in atopic dermatitis (AD) have been accepted for presentation at the American Academy of Dermatology (AAD), March 17-21, 2023, in New Orleans, LA.

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that Palmetto GBA has published a final Local Coverage Determination (LCD) for basivertebral nerve (BVN) ablation that expands access to more than 5 million covered lives.

Longeveron Inc. today announced that the Company will release its fourth quarter and full year 2022 financial results on Friday, March 10, 2023 before the open of the U.S. financial markets.

March 6, 2023-- Quantum-Si Incorporated today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.

NovelMed Therapeutics announced that NM3086, the lead clinical asset in its Properdin-associated Alternative Pathway program, demonstrated favorable efficacy in an animal model of neovascular age-related macular degeneration in rhesus monkeys.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023.

Immuneering Corporation today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business updates.

Allakos Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Rhythm Pharmaceuticals, Inc. today announced that on March 1, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 34,215 shares of its common stock.

Amarin Corporation plc announced that, in the interest of the Company to avoid further proxy contests, all seven independent non-Sarissa board members: Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Dr. Murray Stewart, Jan van Heek and Alfonso “Chito” Zulueta will resign from the Board of Directors, effective immediately.